Skip to main content
main-content
Top

01-01-2015 | Renal cell carcinoma | Article

22. Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies

Authors: MD, FRCPC Christian Kollmannsberger, G. A. Bjarnason, Alain Ravaud

Publisher: Springer International Publishing

Abstract

Targeted therapies have significantly changed the treatment landscape for patients with metastatic renal cell carcinoma (mRCC). TKIs such as sunitinib, sorafenib, pazopanib, and axitinib are all multi-targeted inhibitors which inhibit a variety of targets including the vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor (PDGFR), and others. Temsirolimus and everolimus both interfere with angiogenesis by inhibiting mTOR, a critical regulator within the cell. Bevacizumab blocks the vascular endothelial growth factor (VEGF) pathway by binding to VEGF.

Please log in to get access to this content

Related topics